Yohimbine, How Does it work?

[defcon]

Hey Guys.. i basically understand how the E/C Stack works for fat loss.. but what about with the addition of Yohimbine, any links about it, or how it would be useful? Also.. would it be more beneficial to someone with a lower bf% or a higher bf%.

Lets assume both people are below their bf% setpoint.

[Shao-LiN]

http://www.wannabebigforums.com/showthread.php?s=&threadid=28492&highlight=Lipoderm

[defcon]

Great post thanx man, * saves the ECY for his next cut :P *

[Shao-LiN]

Careful on taking oral ephedra and yohimbine together...I hear there are some side effects to worry about.

[defcon]

Hmm, what kind of effects?

Also, if i do decdie to try itnext cut then i would start @ a very low doseage to see how tolerant i am of it :)

[AJ_11]

I stacked them together with no side effects. But i did start at lower doseages and worked my way up.

[bradley]

If you do decide to make your own ECY stack, I would recommed starting out with 2.5mg of Y. Although I really do not think it is wise to stack yohimbine with ephedrine. Another consideration is you have to plan meals more carefully, due to the fact that yohimbine can cause an increased insulin response when carbs are ingested.


===========
Clin Physiol. 1998 Jan;18(1):69-76.


Cardiovascular effects of ephedrine, caffeine and yohimbine measured by thoracic electrical bioimpedance in obese women.

Waluga M, Janusz M, Karpel E, Hartleb M, Nowak A.

Low caloric diet is a commonly accepted treatment in obesity. However, owing to moderate results, a pharmacological support has been proposed. As some efficacious drugs activate overall sympathetic activity, they might modify functions of the cardiovascular system. Three groups of subjects were studied: (1) nine obese women receiving only a standard hypocaloric diet; (2) nine obese women receiving a standard hypocaloric diet and ephedrine (2 x 25 mg) with caffeine (2 x 200 mg); (3) nine obese women receiving a standard hypocaloric diet and ephedrine (2 x 25 mg) with caffeine (2 x 200 mg) and yohimbine (2 x 5 mg). The cardiovascular state was evaluated by thoracic electrical bioimpedance, automatic sphygmomanometry and continuous ECG recording. In each patient, the haemodynamic study was performed twice: at rest, i.e. before treatment; and after 10 days of treatment. On the same days in each patient, the haemodynamic tests were performed during physical exercises (handgrip stress and cycloergometer exercise). Caffeine and ephedrine had no haemodynamic effect in resting patients. These two drugs led to an increase in ejection fraction during cycloergometer exercise. Addition of yohimbine increased diastolic pressure and heart rate but decreased ejection fraction and stroke index during rest. We also observed that addition of yohimbine decreased ejection fraction during the handgrip and cycloergometer exercise and increased cardiac load during dynamic exercise. Pharmacological supplement of ephedrine and caffeine to a low caloric diet modified the cardiovascular system weakly, but the addition of yohimbine to this regimen attenuated cardiac performance during rest and handgrip and increased cardiac work during dynamic exercise.

PMID: 9545623
===========

Int J Mol Med. 2001 Jul;8(1):103-9.


Divergent effects of an alpha2-adrenergic antagonist on lipolysis and thermogenesis: interactions with a beta3-adrenergic agonist in rats.

Gomez-Ambrosi J, Fruhbeck G, Aguado M, Milagro FI, Margareto J, Martinez AJ.

Department of Physiology and Nutrition, University of Navarra, 31008 Pamplona, Spain.

This study was undertaken in order to test the hypothesis that selective beta3-AR stimulation and simultaneous blockade of alpha2-AR would result in an increase of lipolysis and thermogenesis in rats. Incubation of isolated white adipocytes with the alpha2-AR antagonist yohimbine produced a concentration-dependent increase in glycerol release (P<0.001) for all assayed concentrations (10-12-10-6 M) and potentiated the lipolytic effect of the beta3-AR agonist Trecadrine. However, in vivo administration of yohimbine produced a marked decrease in body temperature (1.3-1.5 degrees C, P<0.001) and blocked the thermogenic effect of Trecadrine when simultaneously administered. A similar response was observed for whole body oxygen consumption. Furthermore, yohimbine did not modify brown adipose tissue oxygen consumption, but blocked the beta3-AR-mediated increase triggered by Trecadrine. Brown adipose tissue UCP-2 and -3 mRNA expression was not changed by yohimbine. In conclusion, the present work indicates that in vitro alpha2-AR blockade by yohimbine potentiates the beta3-AR-mediated stimulation of lipolysis. On the other hand, in vivo alpha2-AR antagonism blocks the thermogenic effects mediated by beta3-AR stimulation, suggesting a possible interplay between the receptors.

PMID: 11408957